.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,671,070

« Back to Dashboard
Patent 7,671,070 protects MOXEZA and VIGAMOX and is included in two NDAs. There have been zero Paragraph IV challenges on Moxeza and Vigamox There are three tentative approvals for the compound protected by this patent. Additional details are available via the generic ingredient links below.

Protection for MOXEZA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 7,671,070

Title:Method of treating ophthalmic infections with moxifloxacin compositions
Abstract:Ophthalmic, otic and nasal compositions containing a new class of antibiotics (e.g., moxifloxacin) are disclosed. The compositions preferably also contain one or more anti-inflammatory agents. The compositions may be utilized to treat ophthalmic, otic and nasal conditions by topically applying the compositions to the affected tissues.
Inventor(s): Cagle; Gerald (Fort Worth, TX), Abshire; Robert L. (Fort Worth, TX), Stroman; David W. (Irving, TX), Yanni; John M. (Burleson, TX)
Assignee: Alcon, Inc. (Hunenberg, CH)
Application Number:10/715,055
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 50th percentile
Forward Citations: 0th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Alcon Pharms Ltd
MOXEZA
moxifloxacin hydrochloride
SOLUTION/DROPS;OPHTHALMIC022428-001Nov 19, 2010RXYes7,671,070*PED► subscribeY
Alcon Pharms Ltd
VIGAMOX
moxifloxacin hydrochloride
SOLUTION/DROPS;OPHTHALMIC021598-001Apr 15, 2003RXYes7,671,070*PED► subscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc